Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting Read more about Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting
US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes Read more about US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes
Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study Read more about Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study
U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer Read more about U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month Read more about Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month
U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor Read more about U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease Read more about US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab Read more about U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting Read more about Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting
Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Read more about Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
